Adial Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Adial Pharmaceuticals reported a net loss of $8.0 million in 2025 and faces substantial doubt about its ability to continue as a going concern, while advancing its lead drug candidate AD04 for Alcohol Use Disorder.
NASDAQ
Adial Pharmaceuticals reports its 2024 financial results, highlighting a net loss but emphasizing strategic focus on AD04 clinical development for alcohol use disorder.
NASDAQ
10-K: Adial Pharmaceuticals Focuses on US Market After Phase 3 Trial Analysis, Secures Additional Funding
Adial Pharmaceuticals is shifting its focus to the US market for its alcohol use disorder treatment, AD04, after analyzing Phase 3 trial data and securing additional funding through warrant exercises.